BeiGene, Ltd. — Q1 2023 Form 10-Q Summary
Issuer note: The filing identifies the registrant as BeiGene, Ltd.; this differs from the company name in the request metadata.
Business context and reporting period
Unaudited results cover the three months ended March 31, 2023, compared with the three months ended March 31, 2022. BeiGene is a global biotechnology company focused on oncology medicines, including BRUKINSA, tislelizumab and pamiparib, plus in-licensed products and collaboration programs. Amounts below are U.S. dollars.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Total revenue | $447.8 million | $306.6 million | +46.0% |
| Net product revenue | $410.3 million | $261.6 million | +56.9% |
| Collaboration revenue | $37.5 million | $45.1 million | -16.7% |
| Gross margin on product sales | 80.1% | 75.1% | +5.0 percentage points |
| Research and development expense | $408.6 million | $389.9 million | +4.8% |
| Selling, general and administrative expense | $328.5 million | $294.6 million | +11.5% |
| Operating loss | $371.3 million | $443.3 million | Loss narrowed |
| Net loss | $348.4 million | $435.2 million | Loss narrowed 19.9% |
| Operating cash flow | $(563.8) million | $(236.6) million | Greater cash use |
BRUKINSA revenue rose 102.6% to $211.4 million; tislelizumab rose 31.0% to $114.9 million. Net loss per share was $0.26, versus $0.33; net loss per ADS was $3.34, versus $4.25. Interest income, net was $16.0 million and other income, net was $18.3 million in Q1 2023.
At March 31, 2023, cash, cash equivalents and restricted cash totaled $3.54 billion, short-term investments were $294.1 million, and total debt was $488.1 million. Current assets were $4.70 billion and current liabilities $1.25 billion. The company reported $309.6 million of accounts receivable, up from $173.2 million at year-end. Cash and cash equivalents alone were $3.54 billion.
Material changes and notable items
- Revenue growth was principally driven by BRUKINSA and tislelizumab sales, with additional contributions from in-licensed products, including POBEVCY and XGEVA. Management attributed China demand growth for BRUKINSA and tislelizumab partly to NRDL reimbursement and broader market access, which offset related price reductions.
- Product gross margin improved largely due to lower unit costs for BRUKINSA and tislelizumab and a higher share of BRUKINSA sales in the product mix.
- Operating cash use increased, primarily reflecting the net loss and growth in operating assets and liabilities, including seasonal receivables and compensation-related payments. Capital expenditures were $125.6 million, versus $45.1 million a year earlier.
- The company recorded a full valuation allowance against net deferred tax assets. It revised Q1 2022 comparative statements for a deferred-tax valuation allowance error; the company said the correction was immaterial to previously issued statements. Revised Q1 2022 net loss increased by $0.9 million to $435.2 million.
- In February 2023, BeiGene and Amgen amended their collaboration: BeiGene stopped sharing LUMAKRAS development costs for January–August 2023 and is preparing a transition plan for the program’s anticipated removal from the collaboration.
Outlook, commitments and risks
Management stated that available cash, cash equivalents and short-term investments were expected to fund operating expenses and capital requirements for at least 12 months after the financial statements were issued. The company expects continued losses and substantial R&D investment; it said existing resources may not fund all planned global development, launches and additional programs. The filing provides no specific revenue or earnings guidance.
Contractual obligations totaled $1.68 billion, including $407.0 million of capital commitments, $560.5 million of remaining Amgen co-development funding, and $281.8 million of debt due within one year. Capital projects include the Hopewell, New Jersey manufacturing and R&D campus and expansions in China. PRC restrictions on currency conversion and transfers, reimbursement and pricing pressure, clinical and regulatory uncertainty, competition, manufacturing and supply dependence, and cross-border data and regulatory requirements are among the disclosed risks. Management reported disclosure controls were effective at a reasonable assurance level and no material quarterly change in internal control over financial reporting.
A post-quarter business update reported that the RATIONALE 305 trial met its overall-survival primary endpoint in advanced gastric or gastroesophageal junction cancer; no new safety signals were reported. The filing also describes a pending BMS-Celgene arbitration concerning ABRAXANE supply and termination. BMS-Celgene counterclaimed for approximately $30 million; BeiGene disputes the claim. No arbitration decision had been issued as of the filing.
Important facts for investors to verify
- Whether BRUKINSA and tislelizumab sales growth and improved product margins continue, particularly amid reimbursement-related price reductions.
- Cash burn, receivables collection and capital spending against the company’s stated minimum 12-month liquidity outlook and substantial contractual commitments.
- Clinical, regulatory and commercial progress for key medicines and candidates, including follow-up implications of the RATIONALE 305 result and the Novartis ociperlimab option.
- Outcome and potential financial impact of the BMS-Celgene arbitration and counterclaim.
- Execution and funding needs for manufacturing expansion, and the effects of PRC regulatory, data-transfer, foreign-exchange and capital-transfer restrictions.